Drp-1, a potential therapeutic target for brain ischaemic stroke

Area of Science:

• Neuroscience
• Cell Biology
• Ischemic Stroke Research

Background:

• CA3 neurons exhibit inherent resistance to ischemia.
• Ischemic preconditioning (IPC) confers tolerance to neuronal injury.
• Identifying molecular mechanisms is crucial for developing neuroprotective therapies.

Purpose of the Study:

• To investigate the role of dynamin-related protein 1 (Drp-1) in neuronal resistance to ischemia.
• To determine if Drp-1 is involved in the neuroprotective effects of IPC.
• To explore Drp-1 as a potential therapeutic target for ischemic stroke.

Main Methods:

• In vivo rat models of global ischemia and IPC.
• In vitro oxygen-glucose deprivation (OGD) in hippocampal neurons.
• Drp-1 silencing (siRNA) and pharmacological inhibition (Mdivi1).
• Western blot, immunohistochemistry, immunofluorescence, and electron microscopy.
• Open-field tests for hippocampal function assessment.

Main Results:

• Mitochondrial Drp-1 (mtDrp-1) was induced by ischemia in CA3 neurons and upregulated by IPC in CA1 neurons.
• Drp-1 suppression increased neuronal vulnerability to OGD and global ischemia.
• Inhibition of Drp-1 impaired spatial information acquisition and encoding.
• Drp-1 inhibition amplified mitochondrial injury and abolished ischemic resistance.

Conclusions:

• Drp-1 enhances the resistance of hippocampal CA3 neurons to global ischemia.
• Drp-1 contributes to the ischemic tolerance conferred by IPC.
• Drp-1 represents a promising therapeutic target for brain ischemic stroke.